Table 3.
Demographics and Outcomes of Intensive Care Unit Patients Receiving Targeted Therapy of CAS, VOR or the Combination for Invasive Fungal Infectionsa
| Demographics and Outcomes | CAS (n = 23) | VOR (n = 29) | CAS+VOR (n = 21) | P-value |
|---|---|---|---|---|
| Sex (male/female) | 15/8 | 16/13 | 11/10 | 0.654 |
| Median age (range) (years) | 69 (28–87) | 67 (30–86) | 66 (25–92) | 0.208 |
| Median hospitalization days (range) | 18 (8–70) | 19 (7–58) | 28 (7–58) | 0.097 |
| Median duration of antifungal agents therapy (range) | 11 (7–27) | 11 (7–28) | 12 (7–26) | 0.969 |
| Infection type (Candida.spp/Aspergillus.spp/others) | 23 (20/2/1) | 29 (20/9/0) | 21 (15/5/1) | > 0.05 |
| Hypoproteinemia (%) | 20 (87.0) | 24 (82.8) | 13 (61.9) | 0.097 |
| Continuous renal replacement therapy (%) | 9 (39.1) | 9 (31.0) | 6 (28.6) | 0.730 |
| Liver function (Child-Pugh A/B/C) | 8/12/3 | 8/20/1 | 6/12/3 | > 0.05 |
| Median creatinine clearance rate (range) (mL/min) | 81.5 (7.7–428.7) | 108.6 (36.5–271.1) | 106.5 (15.1–478.7) | 0.473 |
| Median APACHE II score (range) | 37 (9–42) | 21 (10–34) | 25 (12–30) | 0.201 |
| Median SOFA score (range) | 15 (6–18) | 11 (7–19) | 12 (9–14) | 0.753 |
| Increase in neutrophils (On admission/ infection occurs/at the end of treatment) | 19/23/15 | 20/27/19 | 16/20/15 | > 0.05 |
| Steroid use before or during therapy (%) | 19 (82.6) | 20 (69.0) | 17 (81.0) | 0.504 |
| Mechanical ventilation during therapy (%) | 19 (82.6) | 24 (82.8) | 18 (85.7) | 1.000 |
| Prophylactic antifungal treatment prior to infection (%) | 8 (34.8) | 7 (24.1) | 7 (33.3) | 0.689 |
| Breakthrough infection (%) | 1 (4.3) | 0 (0) | 1 (4.8) | 0.514 |
| Response to therapy (%) | 13 (56.5) | 18 (62.1) | 15 (71.4) | 0.587 |
| IFI-associated death within 90 days (%) | 7 (30.4) | 7 (24.1) | 1 (4.8) | 0.084 |
| All deaths within 90 days (%) | 7 (30.4) | 7 (24.1) | 3 (14.3) | 0.504 |
| All adverse events (%) | 6 (26.1) | 13 (44.8) | 8 (38.1) | 0.377 |
| Liver (%) | 2 (8.7) | 3 (10.3) | 3 (14.3) | 0.805 |
| Renal (%) | 2 (8.7) | 8 (27.6) | 3 (14.3) | 0.212 |
Note: aThe total number of intensive care unit patients receiving targeted therapy of CAS, VOR or the combination was 73.